TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass (TSBL-OAGB)
TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass: Interim Results of a Randomized Trial
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
This is a single-center, prospective, randomized controlled trial comparing two methods for determining biliopancreatic limb length (BPLL) during laparoscopic one-anastomosis gastric bypass (OAGB) in patients with morbid obesity. Eligible patients aged 18-65 years with BMI ≥35 kg/m² (non-Asian) or ≥32.5 kg/m² (Asian populations) who were candidates for primary OAGB were randomized 1:1 using a computer-generated randomization sequence with sequentially numbered, opaque sealed envelopes.
In the intervention (TSBL-based) group, total small bowel length (TSBL) was measured intraoperatively from the ligament of Treitz to the ileocecal valve, and BPLL was calculated as 0.35 × TSBL. In the control (BMI-based) group, BPLL was determined using standard fixed lengths based on BMI category (150 cm, 180 cm, or 200 cm). All other surgical steps were identical between groups.
The primary outcome is percentage excess weight loss (%EWL) assessed longitudinally at baseline, 3, 6, and 12 months. Secondary outcomes include percentage total weight loss (%TWL), BMI, BMI loss, improvement of obesity-related comorbidities, and postoperative complications graded using the Clavien-Dindo classification. Statistical analysis uses linear mixed models to evaluate effects of group, time, and group-by-time interaction.
Because blinding of patients and surgeons was not feasible given the nature of the surgical intervention, outcome assessment relied on objective anthropometric and clinical measures. This record reflects a planned interim analysis conducted on the first 75 of a planned total of 100 enrolled patients, with 51 patients having completed 12-month follow-up at the time of this analysis.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Nurbol Orynbassar
- Telefoonnummer: +77474528797
- E-mail: nurbolorynbassar@gmail.com
Studie Locaties
-
-
-
Almaty, Kazachstan
- Werving
- JSC "National Scientific Center of Surgery named after A.N. Syzganov"
-
Contact:
- Nurbol Orynbassar
- Telefoonnummer: +77474528797
- E-mail: nurbolorynbassar@gmail.com
-
Hoofdonderzoeker:
- Adil Shokebaev
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Age between 18 and 65 years
- BMI ≥35 kg/m² in non-Asian populations or ≥32.5 kg/m² in Asian populations
- Presence or absence of metabolic comorbidities (including type 2 diabetes, hypertension, and dyslipidaemia)
- Eligibility for primary one-anastomosis gastric bypass (OAGB)
- Provision of written informed consent
Exclusion Criteria:
- BMI below the defined thresholds
- Severe decompensated cardiac, pulmonary, hepatic, or renal disease
- Acute inflammatory conditions
- Active gastric or duodenal ulcer
- Psychiatric disorders or substance abuse
- Pregnancy or breastfeeding
- Active malignancy
- Severe intra-abdominal adhesions due to prior surgery
- Secondary obesity related to hypothalamic-pituitary-adrenal axis disorders
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: TSBL-Based Group
Biliopancreatic limb length (BPL) individualized based on intraoperatively measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL.
|
Biliopancreatic limb length individualized intraoperatively based on measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL, prior to laparoscopic one-anastomosis gastric bypass.
|
|
Actieve vergelijker: BMI-Based Group
Biliopancreatic limb length (BPL) determined using standard fixed lengths based on BMI category: 150 cm for BMI 35-39.9,
180 cm for BMI 40-49.9,
200 cm for BMI ≥50.
|
Biliopancreatic limb length determined using standard fixed lengths based on preoperative BMI category (150 cm, 180 cm, or 200 cm), prior to laparoscopic one-anastomosis gastric bypass.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Excess Weight Loss (%EWL)
Tijdsspanne: Baseline, 3 months, 6 months, and 12 months post-surgery
|
EWL defined as the proportion of weight loss relative to excess baseline weight, with ideal body weight defined as BMI 25 kg/m².
Assessed longitudinally over time using linear mixed models.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Total Weight Loss (%TWL)
Tijdsspanne: Baseline, 3 months, 6 months, and 12 months post-surgery
|
TWL assessed as percentage of total body weight loss relative to baseline weight.
Assessed longitudinally over time using linear mixed models.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
BMI Change
Tijdsspanne: Baseline, 3 months, 6 months, and 12 months post-surgery
|
Change in body mass index (BMI, kg/m²) from baseline over time.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
BMI Loss (BMIL)
Tijdsspanne: Baseline, 3 months, 6 months, and 12 months post-surgery
|
Reduction in BMI from baseline, expressed as BMI loss (BMIL).
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
Improvement in Obesity-Related Comorbidities
Tijdsspanne: 12 months post-surgery
|
Change in obesity-related comorbidities, including hypertension and ischemic heart disease, compared between groups.
|
12 months post-surgery
|
|
Postoperative Complications
Tijdsspanne: 12 months post-surgery
|
Postoperative complications documented and categorized according to the Clavien-Dindo classification system, including anaemia, hair loss, and bowel movement disorder.
|
12 months post-surgery
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- TSBL-BMI-OAGB
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .